A mother facing a terminal illness has been refused access to a potentially life-prolonging drug, preventing her from witnessing her daughter’s prom. Jess Duggan, aged 44, is advocating for the availability of the Enhertu drug on the NHS to provide critical additional time for terminally ill mothers to spend with their children. Despite being accessible in Scotland and various other European nations, Enhertu is currently inaccessible to Jess and numerous other women battling breast cancer in England, Wales, and Northern Ireland. Jess, a mother of two from Lewes in East Sussex, expressed her desperation for more time with her family, especially to witness her daughter’s upcoming prom.
Having been diagnosed with breast cancer in 2017, Jess underwent multiple treatments over the years. However, the cancer resurfaced in 2023, spreading to several parts of her body. Despite undergoing various treatments, including a recent chemotherapy, Jess is running out of time as the disease has progressed to her brain and liver. The unavailability of Enhertu has left her and many other women in a dire situation, with limited treatment options and diminishing hope for extended survival.
Breast Cancer Now, a charitable organization, is pushing for immediate action to make Enhertu accessible to those in need. The recent changes in NHS drug spending limits offer a chance to approve Enhertu for breast cancer patients, potentially providing a lifeline to those in critical conditions. As the situation becomes increasingly urgent, the organization is urging pharmaceutical companies and healthcare authorities to collaborate and expedite the process of making Enhertu available to those who could benefit from it.
Jess’s poignant story underscores the importance of timely access to life-extending treatments for patients battling advanced stages of breast cancer. With the clock ticking, the need for swift action and collaboration among stakeholders becomes paramount to prevent further loss and suffering in the breast cancer community.